These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 15307840)

  • 1. CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporin vs. tacrolimus vs. sirolimus.
    Lemahieu WP; Maes BD; Verbeke K; Vanrenterghem Y
    Am J Transplant; 2004 Sep; 4(9):1514-22. PubMed ID: 15307840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of gastric acid suppressants on cytochrome P450 3A4 and P-glycoprotein: consequences for FK506 assimilation.
    Lemahieu WP; Maes BD; Verbeke K; Vanrenterghem Y
    Kidney Int; 2005 Mar; 67(3):1152-60. PubMed ID: 15698457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea.
    Lemahieu W; Maes B; Verbeke K; Rutgeerts P; Geboes K; Vanrenterghem Y
    Am J Transplant; 2005 Jun; 5(6):1383-91. PubMed ID: 15888045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement of hepatic and intestinal CYP3A4 and PGP activity by combined po + iv [14C]erythromycin breath and urine test.
    Lemahieu WP; Maes BD; Ghoos Y; Rutgeerts P; Verbeke K; Vanrenterghem Y
    Am J Physiol Gastrointest Liver Physiol; 2003 Sep; 285(3):G470-82. PubMed ID: 12909563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations of CYP3A4 and P-glycoprotein activity in vivo with time in renal graft recipients.
    Lemahieu WP; Maes BD; Verbeke K; Vanrenterghem YF
    Kidney Int; 2004 Jul; 66(1):433-40. PubMed ID: 15200453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus.
    Lemahieu WP; Hermann M; Asberg A; Verbeke K; Holdaas H; Vanrenterghem Y; Maes BD
    Am J Transplant; 2005 Sep; 5(9):2236-43. PubMed ID: 16095503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine.
    Lown KS; Mayo RR; Leichtman AB; Hsiao HL; Turgeon DK; Schmiedlin-Ren P; Brown MB; Guo W; Rossi SJ; Benet LZ; Watkins PB
    Clin Pharmacol Ther; 1997 Sep; 62(3):248-60. PubMed ID: 9333100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
    Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
    Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in Type 1 and Type 2 intracytoplasmic cytokines, detected by flow cytometry, according to immunosuppression (cyclosporine A vs. tacrolimus) in stable renal allograft recipients.
    Rostaing L; Puyoo O; Tkaczuk J; Peres C; Rouzaud A; Cisterne JM; de Preval C; Ohayon E; Durand D; Abbal M
    Clin Transplant; 1999 Oct; 13(5):400-9. PubMed ID: 10515221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic interaction between cyclosporine and sirolimus.
    Bai S; Stepkowski SM; Kahan BD; Brunner LJ
    Transplantation; 2004 May; 77(10):1507-12. PubMed ID: 15239612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
    Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic polymorphisms in CYP3A5 and MDR1 genes and their correlations with plasma levels of tacrolimus and cyclosporine in renal transplant recipients.
    Mendes J; Martinho A; Simoes O; Mota A; Breitenfeld L; Pais L
    Transplant Proc; 2009 Apr; 41(3):840-2. PubMed ID: 19376366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclosporine and sirolimus interaction in a kidney transplant patient.
    Dabrowska-Zamojcin E; Pawlik A; Domański L; Rózański J; Droździk M
    Transplant Proc; 2005 Jun; 37(5):2317-9. PubMed ID: 15964407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of CYP3A4*1B genotype with Cyclosporin A pharmacokinetics in renal transplant recipients: A meta-analysis.
    Wang CE; Lu KP; Chang Z; Guo ML; Qiao HL
    Gene; 2018 Jul; 664():44-49. PubMed ID: 29678659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.
    Jun KR; Lee W; Jang MS; Chun S; Song GW; Park KT; Lee SG; Han DJ; Kang C; Cho DY; Kim JQ; Min WK
    Transplantation; 2009 Apr; 87(8):1225-31. PubMed ID: 19384171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation.
    Goto M; Masuda S; Saito H; Uemoto S; Kiuchi T; Tanaka K; Inui K
    Pharmacogenetics; 2002 Aug; 12(6):451-7. PubMed ID: 12172213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients.
    Cho JH; Yoon YD; Park JY; Song EJ; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
    Transplant Proc; 2012 Jan; 44(1):109-14. PubMed ID: 22310591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoantibodies against cytochrome P450s in sera of children treated with immunosuppressive drugs.
    Lytton SD; Berg U; Nemeth A; Ingelman-Sundberg M
    Clin Exp Immunol; 2002 Feb; 127(2):293-302. PubMed ID: 11876753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients.
    von Ahsen N; Richter M; Grupp C; Ringe B; Oellerich M; Armstrong VW
    Clin Chem; 2001 Jun; 47(6):1048-52. PubMed ID: 11375290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.